Hyundai Bio Announces Clinical Strategy for Antiviral Drug 'Zefti' in the U.S.
5 Articles
5 Articles
Hyundai Bioscience announced on the 26th that it attended the Infectious Diseases Week held in Washington, D.C. The company presented its clinical strategy for Zefty, a candidate substance that inhibits viruses. Phase 2 and 3 clinical trials for Zefty are currently underway in Vietnam targeting dengue fever patients. Vietnam sees over 400,000 dengue fever cases annually. This is because the hot and humid weather makes it easy for mosquitoes that…
(Seoul = Yonhap News) Reporter Park Sang-hyun = Hyundai Bioscience announced in the U.S. its strategy for the Phase 2/3 clinical trials in Vietnam of its universal antiviral candidate 'Zefti'...
Hyundai Bioscience’s universal antiviral candidate, ‘Zefti (CP-COV03)’, was presented at the official academic program of ‘IDWeek 2026’, held in Washington, D.C., from the 21st to the 24th. IDWeek is one of the largest infectious disease conferences in the United States.
The logo of Hyundai Bioscience. [Photo courtesy of Hyundai Bioscience] South Korea’s Hyundai Bioscience announced on Oct. 26 that its broad-spectrum antiviral drug candidate Xafty was featured at IDWeek 2026, a major infectious disease conference in Washington, D.C., last week. The Seoul-based company said that University of California, San Diego Prof. Davey Smith presented the clinical development strategy of Xafty during the conference, which …
[Digital Daily Reporter Wang Jin-hwa] Hyundai Bioscience has disclosed the current status of the clinical development of its universal antiviral candidate, 'Jefty,' for dengue fever to the U.S. infectious disease academic community. The company shared initial safety data from clinical trials currently underway in Vietnam and presented development plans to expand the scope of treatment to various viral infectious diseases in the future. Hyundai …
Coverage Details
Bias Distribution
- 67% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
